SYPHILIS TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

The Global Syphilis Testing Market Size and Forecast – 2025 to 2032

The Global Syphilis Testing Market is estimated to be valued at USD 1.19 Bn in 2025 and is expected to reach USD 2.61 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 11.9% from 2025 to 2032. This significant growth is driven by increasing awareness about sexually transmitted diseases, advancements in diagnostic technologies, and supportive government initiatives aimed at controlling the spread of syphilis globally.

Key Takeaways of The Global Syphilis Testing Market

• In the global syphilis testing market, the primary and secondary syphilis segment is expected to lead the market, accounting for 55.4% of the market share in 2025.
• Serological tests are expected to dominate the market, capturing 75.3% of the market share in 2025.
• The laboratory testing segment is projected to remain the most prevalent method, holding a 70.8% share in 2025.
• North America is expected to lead the market, holding a share of 41.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 24.4% in 2025.

Market Overview

A market trends indicate a rising adoption of rapid and point-of-care testing methods, which offer quicker and more accurate results compared to traditional laboratory-based tests. Additionally, the integration of digital health solutions and increasing investments in research and development are enhancing early detection and management of syphilis. The growing prevalence of syphilis in key regions and expanding healthcare infrastructure further support the market expansion during the forecast period.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Syphilis Testing Market Insights, By Type of Syphilis - Primary and Secondary Syphilis Drive the Market Dominance Due to High Infectiousness of Syphilis

In terms of the type of syphilis, the primary and secondary syphilis segment is expected to dominate with a share of 55.4% in 2025. A primary case usually shows up with a sore or ulcer at the infection site, while the secondary stage has flu-like symptoms, along with rashes that are the typical marks of the disease, thus leading individuals to visit a doctor. The fact that these stages are both visible and symptomatic predisposes to testing and hence, the demand for diagnostic tools for these phases increases.

The visibility and symptomatic nature of primary and secondary syphilis increase the likelihood of early diagnosis. As these stages are both contagious and detectable, they significantly contribute to the dominance of this segment in the global syphilis testing market.

Syphilis Testing Market Insights, By Test Methodology - Serological Tests Lead as Preferred Methodology Amid Accessibility and Accuracy

The serological tests segment is expected to dominate the global syphilis testing market, with a share of 75.3% in 2025, covering both non-treponemal (e.g., RPR, VDRL) and treponemal (e.g., TPHA, FTA-ABS) assays. The high usage of these tests is mainly due to their proven reliability, cost-effectiveness, and ease of use in different healthcare settings. Serological tests have been for a long time the main method for syphilis screening and diagnosis due to their combination of sensitivity and specificity that satisfies clinical needs.

In August 2024, QuidelOrtho Corporation, a leader in infectious disease testing, received U.S. FDA 510(k) clearance for its VITROS Syphilis Assay, which is now available on the VITROS 3600, 5600, and XT 7600 Integrated Systems. The assay, designed for the qualitative detection of antibodies to Treponema pallidum in human serum and plasma, is crucial in diagnosing syphilis when used alongside non-treponemal tests and clinical findings.

Syphilis Testing Market Insights, By Location of Testing - Laboratory Testing Maintains Prominence Through Comprehensive Capabilities and Infrastructure

The laboratory testing segment is projected to lead with a 70.8% share in 2025, making it the most significant segment of the global syphilis testing market. This rank is validated by the fact that laboratory facilities are the best for accurate, reliable, and multiplex diagnostic capabilities and thus, relying on the infrastructure and technical expertise of the laboratories.

The laboratories conduct a wide variety of tests, including serological assays and molecular diagnostics, which often demand sophisticated equipment and highly qualified personnel, and they do so in a controlled environment.

Regional Insights

To learn more about this report, Download Free Sample

North America Syphilis Testing Market Analysis and Trends

In 2025, North America will still be the largest market for syphilis testing, accounting for 41.3% of the global market, mainly due to its well-established healthcare system, extensive awareness programs, and government initiatives that control STIs. In addition, the whole process of screening and detection is supported by timely diagnosis and an efficient healthcare system.

In March 2023, the Centers for Disease Control and Prevention (CDC) partnered with OraSure Technologies and Emory University to launch the Together TakeMeHome (TTMH) program, offering free online ordering of Human Immunodeficiency Virus (HIV) self-test kits to individuals aged 17 and above across the United States (U.S.) and Puerto Rico to reduce stigma and improve access to testing.

Asia Pacific Syphilis Testing Market Analysis and Trends

The Asia Pacific region is the most rapidly expanding area in the syphilis testing market with an estimated 24.4% share in 2025, due to the rising healthcare awareness, increasing government funding for public health, and the growing diagnostic infrastructure. Even though nations like India and China are in the process of development, they are investing large sums in healthcare accessibility and disease prevention which is resulting in a significant increase in testing volumes.

The presence of multi-national diagnostic companies and local players could be seen as factors that promote competitive pricing and the provision of testing solutions fitting the specific regional needs. Besides, urbanization and better healthcare accessibility are also factors contributing to the higher demand for syphilis screening.

Global Syphilis Testing Market Outlook for Key Countries

U.S. Syphilis Testing Market Analysis and Trends

The U.S. syphilis testing market is still very advanced and competitive, sustained by tough public health regulations and large-scale screening programs. Roche Diagnostics, Siemens Healthineers, and other companies do the cutting-edge testing platforms, emphasizing speed and accuracy that the U.S. market needs. The continuous funding for disease surveillance and awareness campaigns that the country allocates to STI prevalence reduction drives testing uptake.

In September 2025, Infectious Disease Advisor, a U.S.-based medical news platform under Haymarket Media, reported a sharp resurgence of syphilis cases across the U.S., citing Centers for Disease Control and Prevention (CDC) data showing rates rising from 39.6 per 100,000 in 2019 to 62.5 per 100,000 in 2023  the highest since 1950.

China Syphilis Testing Market Analysis and Trends

The syphilis testing market in China is changing very fast due to the recent government measures that aim to strengthen the disease prevention networks and increase the lab's capacity. The repercussions of this change can be seen in the interest of companies like Shenzhen Bioeasy Biotechnology, which is a major domestic diagnostics company, and foreign firms like Abbott that are investing in the country's production and distribution networks. The modernization of healthcare in cities, government-sponsored public testing campaigns, and the gradual increase in screening penetration are all factors that are driving the growth in testing demand.

In December 2023, the Pingxiang Christian Volunteer Team in Jiangxi, China, partnered with the Pingxiang Center for Disease Control and Prevention (CDC) to run a 10-day anti-AIDS campaign featuring rapid AIDS and syphilis screenings, health lectures, and counseling sessions across local schools and hospitals.

India Syphilis Testing Market Analysis and Trends

The syphilis testing market in India is primarily driven by the government’s STI elimination initiative under the national health programs that give importance to the area for growth. The presence of companies like Transasia Bio-Medicals and Beckman Coulter guarantees the availability of syphilis test kits not just in rural but also in urban areas. Awareness of public health is increasing, the healthcare system is being improved, and the collaboration between the public and private sectors is making the testing more accessible.

In April 2025, the William J. Clinton Foundation (WJCF), an affiliate of the Clinton Health Access Initiative (CHAI), partnered with the Government of West Bengal, India, to launch a triple elimination initiative targeting the prevention of mother-to-child transmission of Human Immunodeficiency Virus (HIV), syphilis, and hepatitis B (HBV). The program aims to strengthen maternal and child healthcare by ensuring early testing, treatment, and follow-up for pregnant women, with the goal of every baby being born infection-free.

Germany Syphilis Testing Market Analysis and Trends

Germany syphilis testing market benefits from an advanced healthcare system that prioritizes early disease detection and has a wide range of laboratories. Bio-Rad Laboratories and EUROIMMUN are among the companies that have been making great contributions by providing innovative immunoassay and rapid testing products. The government has put in place policies that promote thorough STI screening, particularly in disadvantaged groups, and this is further supported by well-established reimbursement structures.

In August 2025, altona Diagnostics, a Germany-based molecular diagnostics company, launched the AltoStar Treponema pallidum PCR Kit 1.5 RUO as part of its sexually transmitted infections panel. The new real-time PCR reagent system enables qualitative detection of Treponema pallidum DNA, the bacterium responsible for syphilis, and expands altona’s AltoStar portfolio for more comprehensive infectious disease research.

End User Feedback and Unmet Needs in the Global Syphilis Testing Market

• Feedback from end users in the main sectors like health providers, diagnostic labs, and government health agencies has shown that the global syphilis testing market is something that has both satisfied and annoyed users. A good instance of this is the rapid adoption of point-of-care testing, which has been recognized for its user-friendly nature, quickness, and precision. Practitioners in areas that are not easily accessible to centralized labs have found the capacity to get results quickly a medical benefit. However, the issue that the users keep mentioning is that poor areas still have limited access to these tests because of the high prices and narrow distribution networks, which in turn, impedes the effectiveness of syphilis control programs in these areas.
• As the situation stands, there is still no solution to certain issues that have to do with the affordability and customization of the tests. Overcoming the barriers that are around the test affordability, the customization of healthcare settings, and the distribution networks could result in the opening up of great growth opportunities. If these areas are focused on, then the manufacturers and policymakers will not only be able to retain customers but also trigger new ideas and enlarge the market, thereby making the syphilis testing process more efficient and equitable all over the world.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In April 2025, the Pan American Health Organization and World Health Organization (PAHO/WHO) international public health agencies launched the “Strengthening the EMTCT Plus Strategy within the Maternal and Child Health Framework” project to eliminate mother-to-child transmission of Human Immunodeficiency Virus (HIV), syphilis, and hepatitis B in the Caribbean.
• In March 2025, the Canadian Institutes of Health Research (CIHR), in collaboration with Indigenous leaders, launched the Ayaangwaamiziwin Centre, a USD 7 million Indigenous-led initiative targeting syphilis in Canada’s Prairie and northern communities. The program focuses on culturally safe testing, treatment, and community-based care, addressing the high infection rates among Indigenous populations. By combining community leadership with mobile outreach and modern diagnostics, this initiative aims to reduce barriers, improve adherence, and build trust in healthcare interventions for vulnerable populations.
• In August 2024, NOWDiagnostics, a leader in over-the-counter diagnostic tests, received U.S. FDA De Novo marketing authorization for its First to Know Syphilis Test. This test is the first and only rapid syphilis test in the U.S. that offers in-home results in just 15 minutes with a single drop of blood. Proven in a clinical study of 1,270 participants, the test boasts high accuracy, with a 99.5% negative percent agreement and a 93.4% positive percent agreement.
• In August 2024, QuidelOrtho Corporation received U.S. FDA 510(k) clearance for its VITROS Syphilis Assay, expanding its offering for syphilis diagnosis on the VITROS 3600, 5600, and XT 7600 systems. This automated assay, designed to detect antibodies to Treponema pallidum, aids in syphilis diagnosis when used alongside non-treponemal tests and clinical findings. With syphilis cases in the U.S. rising, the VITROS syphilis assay offers an essential tool for healthcare providers to provide timely and accurate diagnosis, crucial for controlling the disease.

Top Strategies Followed by the Global Syphilis Testing Market Players

• Industry leaders spend a lot of money on R&D intending to be at the forefront of the market with innovative, high-performance products that provide outstanding accuracy, faster results, and are easy to use. Such companies have the distributors of diagnostics at the hospitals and clinics in mind and are constantly on the lookout for the latest technology in diagnostic imaging such as point-of-care, multiplex assays, and automation.
  • Established market leaders such as Abbott Laboratories (U.S.), Siemens Healthineers (Germany), and bioMérieux SA (France) invest heavily in Research and Development (R&D) to deliver advanced diagnostic systems for syphilis testing. For instance, Abbott’s Architect Syphilis TP assay and Siemens’ ADVIA Centaur Syphilis Assay provide high sensitivity and automation for large-scale hospital laboratories.

• Mid-level players in the syphilis testing market have a different strategy, mainly turning to providing quality solutions that are cost-effective at the same time. This group of companies targets the price-sensitive customers, including the clinics and public health programs of the developing regions where the tight budget calls for esthetically priced yet trustworthy testing options.
  • Mediumpace players like Trinity Biotech (Ireland), Sekisui Diagnostics (Japan), and Chembio Diagnostics (U.S.) are developing moneysaving options that would be the same in price with quality through allowing to keep the latter. For instance, the DPP Syphilis Screen & Confirm Assay of Chembio not only provides but also dual testing syphilis antibodies rapid capabilities making it perfect for resource limited areas.

• The small companies in the global syphilis testing market make their way to the niche by putting their focus on certain product features or novel diagnostic methods that separate them from the bigger companies. Besides, the playbots often exploit the new technologies like digital health integrations, microfluidics, or biosensors to make new testing formats that cater to certain clinical requirements or convenience factors.
  • Niche innovation is the main focus of small-scale enterprises like CTK Biotech (USA), Atlas Link Biotech (China) and Aspen Diagnostics (India) that often use technologies like microfluidics, biosensors and smartphone platforms for detection. For example, the OnSite Rapid Syphilis Test from CTK Biotech offers rapid results with a very little infrastructure requirement thus being a good candidate for community and remote health programs.

Market Report Scope

Syphilis Testing Market Report Coverage

Syphilis Testing Market Dynamics

To learn more about this report, Download Free Sample

Syphilis Testing Market Driver - Increasing Global Prevalence of Syphilis and Other Sexually Transmitted Infections

The upward trend in syphilis and other Sexually Transmitted Infections (STIs) is a major reason why advanced syphilis testing solutions are in demand. Social behavior is changing, condom use is decreasing, and sexual health education is still limited in many areas, hence the steadily rising number of infections. This public health issue has been worsened by the presence of HIV co-infections which are treated through frequent and accurate diagnostic testing. Moreover, urbanization and globalization have amplified the spread of infections among various populations, thereby compelling health care providers and governments to make early detection a priority through widespread screening programs.

In September 2025, the World Health Organization (WHO) a specialized agency of the United Nations for global public health released updated data showing that more than 1 million curable Sexually Transmitted Infections (STIs) are acquired every day worldwide among people aged 15–49. The report estimated 8 million adults infected with syphilis in 2022 and 1.1 million pregnant women affected, leading to over 390,000 adverse birth outcomes. It also highlighted that 520 million people live with herpes simplex virus type 2 (HSV-2) and 300 million women have human papillomavirus (HPV), responsible for over 311,000 cervical cancer deaths annually.

Syphilis Testing Market Opportunity - Expansion of Over-the-Counter and At-Home Testing Solutions

The global syphilis testing market is going to be very much influenced by the growing availability and acceptance of Over-The-Counter (OTC) and at-home testing solutions. Consumers have shifted towards self-testing kits that do not require clinical visits to protect their privacy and to have more convenience in healthcare, which is the result of increasing awareness of Sexually Transmitted Infections (STIs) and the rising demand for privacy and convenience in healthcare.

In May 2025, Wisp, a U.S.-based women’s telehealth company serving over 1.5 million customers launched its new diagnostics vertical, expanding into at-home testing and follow-up care for sexual and reproductive health. The new Wisp At-Home Testing & Follow-Up Care service allows users to collect samples for conditions such as chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium (Mgen) from home and receive results within 3–5 business days through CLIA/CAP-accredited labs.

Analyst Opinion (Expert Opinion)

• The confluence of factors is driving the syphilis testing market with technological advancements in diagnostic tools playing a central role. The more rapid, accurate, and cost-effective testing methods, such as serological tests and point-of-care diagnostic kits, are making syphilis detection more accessible, especially in underserved regions. Along with this, rising awareness and regulatory support from the healthcare sector are creating favorable conditions for the market to expand. Besides, the government and health agencies worldwide are prioritizing STD prevention and control programs thus increasing the demand for better syphilis testing. However, the market has to deal with the stigma associated with STDs that may slow down testing, and the lack of infrastructure in developing regions that would otherwise make testing accessible.
• One of the markets' future opportunities lies in AI and machine learning adoption in diagnostic tools which would lead to improved test accuracy and processing efficiency. Industry collaborations like those between public health organizations and private diagnostic companies are likely testing accessibility to improve, especially in low-resource settings. Recent initiatives, such as the World Health Organization's efforts to eliminate syphilis as a public health problem by 2030 are expected to influence the market’s growth trajectory.

Market Segmentation

• Type of Syphilis Insights (Revenue, USD Bn, 2020 - 2032)
  • Primary and Secondary Syphilis
  • Latent and Tertiary Syphilis
• Test Methodology Insights (Revenue, USD Bn, 2020 - 2032)
  • Serological Tests
    • Non-Treponemal Tests (e.g., RPR, VDRL)
    • Treponemal Tests (e.g., TPHA, FTA-ABS)
  • Molecular Diagnostics
    • Nucleic Acid Amplification Tests (NAATs)
    • Polymerase Chain Reaction (PCR)
• Location of Testing Insights (Revenue, USD Bn, 2020 - 2032)
  • Laboratory Testing
  • Point-of-Care (POC) Testing
• Specimen Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Serum/Plasma
  • Whole Blood
  • Oral Fluid
  • Dried Blood Spot (DBS)
• Product Format Insights (Revenue, USD Bn, 2020 - 2032)
  • Diagnostic Kits
  • Reagents and Consumables
  • Instruments and Analyzers
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chemiluminescent Immunoassay (CLIA)
  • Lateral Flow Assays (LFA)
  • Rapid Plasma Reagin (RPR)
  • Treponemal Particle Agglutination (TPPA)
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Diagnostic Laboratories
  • Point-of-Care (POC) Settings
  • Home Care/Self-Testing
  • Others (Academic and Research Institutes)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Roche Diagnostics
  • Abbott Laboratories
  • BD (Becton, Dickinson and Company)
  • Siemens Healthineers
  • bioMerieux
  • Hologic
  • Cepheid
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific
  • Ortho Clinical Diagnostics
  • QuidelOrtho
  • Trinity Biotech
  • SD Biosensor
  • Healgen Scientific
  • Mologic

Sources

Primary Research Interviews

• Industry Stakeholders List
• National Institutes of Health (NIH)
• Centers for Disease Control and Prevention (CDC)
• End Users List
• Public Health England (PHE)
• Médecins Sans Frontières (MSF)

Government and International Databases

• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• European Centre for Disease Prevention and Control (ECDC)
• National Institutes of Health (NIH)
• United Nations Population Fund (UNFPA)
• Global Health Data Exchange (GHDx)

Trade Publications

• The Lancet Infectious Diseases
• Journal of Clinical Microbiology
• Sexually Transmitted Diseases Journal
• Clinical Infectious Diseases
• Diagnostic Microbiology and Infectious Disease
• Journal of Medical Microbiology

Academic Journals

• Clinical Chemistry
• Journal of Clinical Microbiology
• Sexually Transmitted Diseases
• The Lancet Infectious Diseases
• Journal of Medical Microbiology
• Diagnostic Microbiology and Infectious Disease

Reputable Newspapers

• The New York Times
• The Guardian
• The Washington Post
• BBC News
• The Times of India
• Al Jazeera

Industry Associations

• American Society for Microbiology (ASM)
• International Union Against Sexually Transmitted Infections (IUSTI)
• European Society for Clinical Microbiology and Infectious Diseases (ESCMID)
• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National Institutes of Health (NIH)

Public Domain Resources

• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO)
• National Institutes of Health (NIH)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Global Health Data Exchange (GHDx)

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years